Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ebang, 3D Systems, Amdocs, and FibroGen and Encourages Investors to Contact the Firm
April 14, 2021 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
February 18, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close....
FibroGen to Present at Upcoming Investor Conferences
February 12, 2021 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
FibroGen to Report Second Quarter 2020 Financial Results
July 23, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will...
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
May 08, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, May 08, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May...
FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results
March 02, 2020 16:01 ET
|
FibroGen, Inc
Roxadustat NDA submission accepted with PDUFA date of December 20, 2020Pamrevlumab pivotal trials for treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic...
FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results
February 18, 2020 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Feb. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2019 financial results after market close on Monday, March 2, 2020....
FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease
December 23, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for...
FibroGen Announces Roxadustat Inclusion in China’s National Reimbursement Drug List
December 02, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Dec. 02, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported roxadustat has been included on the updated National Reimbursement Drug List (NRDL) released by China’s...
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
November 08, 2019 14:10 ET
|
FibroGen, Inc
Roxadustat cardiovascular safety comparable to placebo in non-dialysis dependent (NDD) patients, as assessed by Major Adverse Cardiovascular Events (MACE) and MACE+ Roxadustat did not increase risk...